2019
Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma
Lazova R, Smoot K, Anderson H, Powell MJ, Rosenberg AS, Rongioletti F, Pilloni L, D'Hallewin S, Gueorguieva R, Tantcheva‐Poór I, Obadofin O, Camacho C, Hsi A, Kluger HH, Fadare O, Seeley EH. Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma. Journal Of Cutaneous Pathology 2019, 47: 226-240. PMID: 31697431, DOI: 10.1111/cup.13610.Peer-Reviewed Original Research
2016
Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms
Lazova R, Seeley EH, Kutzner H, Scolyer RA, Scott G, Cerroni L, Fried I, Kozovska ME, Rosenberg AS, Prieto VG, Shehata BM, Durham MM, Henry G, Rodriguez-Peralto JL, Riveiro-Falkenbach E, Schaefer JT, Danialan R, Fraitag S, Vollenweider-Roten S, Sepehr A, Sangueza M, Hijazi N, Corredoira Y, Kowal R, Harris OM, Bravo F, Boyd AS, Gueorguieva R, Caprioli RM. Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. Journal Of The American Academy Of Dermatology 2016, 75: 1176-1186.e4. PMID: 27502312, PMCID: PMC5112112, DOI: 10.1016/j.jaad.2016.07.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overChildChild, PreschoolDiagnosis, DifferentialFemaleHumansLymphatic MetastasisMaleMass SpectrometryMelanomaMiddle AgedNeoplasm Recurrence, LocalNevus, Epithelioid and Spindle CellProteinsRetrospective StudiesRisk AssessmentSentinel Lymph Node BiopsySkin NeoplasmsTreatment OutcomeTumor BurdenYoung AdultConceptsAtypical spitzoid neoplasmsClinical group 1Clinical behaviorSpitzoid melanomaHistopathological diagnosisGroup 1Spitzoid neoplasmsClinical group 2Greater tumor thicknessRetrospective collaborative studyAggressive clinical behaviorClinical outcomesRisk stratificationTumor thicknessPoor outcomeWorse clinical behaviorGroup 2Older ageClinical groupsDiagnosisSpitz neviMelanomaStrong associationProteomic signaturePatients